

Pro-nociceptive migraine mediator CGRP provides neuroprotection of sensory, cortical and cerebellar neurons via multi-kinase signaling

Abushik P., Bart G., Korhonen P., Leinonen H., Giniatullina R., Sibarov D., Levonen A., Malm T., Antonov S., Giniatullin R.

Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia

Abstract

© 2016, © International Headache Society 2016. Background: Blocking the pro-nociceptive action of CGRP is one of the most promising approaches for migraine prophylaxis. The aim of this study was to explore a role for CGRP as a neuroprotective agent for central and peripheral neurons. Methods: The viability of isolated rat trigeminal, cortical and cerebellar neurons was tested by fluorescence vital assay. Engagement of Nrf2 target genes was analyzed by qPCR. The neuroprotective efficacy of CGRP in vivo was tested in mice using a permanent cerebral ischemia model. Results: CGRP prevented apoptosis induced by the amino acid homocysteine in all three distinct neuronal populations. Using a set of specific kinase inhibitors, we show the role of multi-kinase signaling pathways involving PKA and CaMKII in neuronal survival. Forskolin triggered a very similar signaling cascade, suggesting that cAMP is the main upstream trigger for multi-kinase neuroprotection. The specific CGRP antagonist BIBN4096 reduced cellular viability, lending further support to the proposed neuroprotective function of CGRP. Importantly, CGRP was neuroprotective against permanent ischemia in mice. Conclusion: Our data show an unexpected 'positive' role for the endogenous pro-nociceptive migraine mediator CGRP, suggesting more careful examination of migraine prophylaxis strategy based on CGRP antagonism although it should be noted that homocysteine induced apoptosis in primary neuronal cell culture might not necessarily reproduce all the features of cell loss in the living organism.

<http://dx.doi.org/10.1177/0333102416681588>

Keywords

CaMKII, cAMP, cerebellum, CGRP, cortex, ischemia, migraine, neuroprotection, trigeminal ganglion

References

- [1] Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 2013; 33: 629-808
- [2] Moskowitz MA. Genes, proteases, cortical spreading depression and migraine: Impact on pathophysiology and treatment. *Funct Neurol* 2007; 22: 133-136.

- [3] Tozzi A, de Iure A, Di Filippo M, Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. *Proc Natl Acad Sci USA* 2012; 109: 18985-18990.
- [4] Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. *Physiol Rev* 2001; 81: 1065-1096.
- [5] de Vries B, Eising E, Broos LA, RNA expression profiling in brains of familial hemiplegic migraine type 1 knock-in mice. *Cephalalgia* 2014; 34: 174-182.
- [6] Pietrobon D, Moskowitz MA. Pathophysiology of migraine. *Annu Rev Physiol* 2013; 75: 365-391.
- [7] Shatillo A, Salo RA, Giniatullin R, Involvement of NMDA receptor subtypes in cortical spreading depression in rats assessed by fMRI. *Neuropharmacology* 2015; 93: 164-170.
- [8] Lauritzen M, Dreier JP, Fabricius M, Clinical relevance of cortical spreading depression in neurological disorders: Migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. *J Cereb Blood Flow Metab* 2011; 31: 17-35.
- [9] Kruit MC, van Buchem MA, Launer LJ, Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study. *Cephalalgia* 2010; 30: 129-136.
- [10] Hougaard A, Amin FM, Ashina M. Migraine and structural abnormalities in the brain. *Curr Opin Neurol* 2014; 27: 309-314.
- [11] Bashir A, Lipton RB, Ashina S, Migraine and structural changes in the brain: A systematic review and meta-analysis. *Neurology* 2013; 81: 1260-1268.
- [12] Colombo B, Dalla Libera D, Comi G. Brain white matter lesions in migraine: What's the meaning? *Neurol Sci* 2011; 32: S37-S40.
- [13] Russell FA, King R, Smillie SJ, Calcitonin gene-related peptide: Physiology and pathophysiology. *Physiol Rev* 2014; 94: 1099-1142.
- [14] Greco R, Tassorelli C, Sandrini G, Role of calcitonin gene-related peptide and substance P in different models of pain. *Cephalalgia* 2008; 28: 114-126.
- [15] Messlinger K, Lennerz JK, Eberhardt M, CGRP and NO in the trigeminal system: Mechanisms and role in headache generation. *Headache* 2012; 52: 1411-1427.
- [16] Ma W, Chabot JG, Powell KJ, Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. *Neuroscience* 2003; 120: 677-694.
- [17] Giniatullin R, Nistri A, Fabbretti E. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. *Mol Neurobiol* 2008; 37: 83-90.
- [18] Giniatullin R, Nistri A. Desensitization properties of P2X3 receptors shaping pain signaling. *Front Cell Neurosci* 2013; 7: 245-245.
- [19] Edvinsson L, Delgado-Zygmunt T, Ekman R, Involvement of perivascular sensory fibers in the pathophysiology of cerebral vasospasm following subarachnoid hemorrhage. *J Cereb Blood Flow Metab* 1990; 10: 602-607.
- [20] Schebesch KM, Herbst A, Bele S, Calcitonin-gene related peptide and cerebral vasospasm. *J Clin Neurosci* 2013; 20: 584-586.
- [21] Abushik PA, Niittykoski M, Giniatullina R, The role of NMDA and mGluR5 receptors in calcium mobilization and neurotoxicity of homocysteine in trigeminal and cortical neurons and glial cells. *J Neurochem* 2014; 129: 264-274.
- [22] Simonetti M, Fabbro A, D'Arco M, Comparison of P2X and TRPV1 receptors in ganglia or primary culture of trigeminal neurons and their modulation by NGF or serotonin. *Mol Pain* 2006; 2: 11-11.
- [23] Mironova EV, Evstratova AA, Antonov SM. A fluorescence vital assay for the recognition and quantification of excitotoxic cell death by necrosis and apoptosis using confocal microscopy on neurons in culture. *J Neurosci Methods* 2007; 163: 1-8.
- [24] Courtney MJ, Akerman KE, Coffey ET. Neurotrophins protect cultured cerebellar granule neurons against the early phase of cell death by a two-component mechanism. *J Neurosci* 1997; 17: 4201-4211.
- [25] Dhungana H, Malm T, Denes A, Aging aggravates ischemic stroke-induced brain damage in mice with chronic peripheral infection. *Aging Cell* 2013; 12: 842-850.
- [26] Shuaib A, Xu Wang C, Yang T, Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. *Stroke* 2002; 33: 3033-3037.
- [27] Costa C, Tozzi A, Rainero I, Cortical spreading depression as a target for anti-migraine agents. *J Headache Pain* 2013; 14: 62-62.
- [28] Vincent M, Hadjikhani N. The cerebellum and migraine. *Headache* 2007; 47: 820-833.
- [29] Edvinsson L, Eftekhari S, Salvatore CA, Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. *Mol Cell Neurosci* 2011; 46: 333-339.

- [30] Satoh L, Okamoto SI, Cui J, Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers. *Proc Natl Acad Sci USA* 2005; 103: 768-773.
- [31] Lastres-Becker I, García-Yagüe AJ, Scannevin RH, Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's Disease. *Antioxid Redox Signal* 2016; 25: 61-77.
- [32] Oterino A, Toriello M, Valle N, The relationship between homocysteine and genes of folate-related enzymes in migraine patients. *Headache* 2010; 50: 99-108.
- [33] Schürks M, Rist PM, Kurth T. Sex hormone receptor gene polymorphisms and migraine: A systematic review and meta-analysis. *Cephalalgia* 2010; 30: 1306-1328.
- [34] Kowa H, Yasui K, Takeshima T, The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. *Am J Med Genet* 2000; 96: 762-764.
- [35] Broch OJ, Ueland PM. Regional distribution of homocysteine in the mammalian brain. *J Neurochem* 1984; 43: 1755-1757.
- [36] Lauritzen M, Rice ME, Okada Y, Quisqualate, kainate and NMDA can initiate spreading depression in the turtle cerebellum. *Brain Res* 1988; 475: 317-327.
- [37] Eftekhari S, Gaspar RC, Roberts R, Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography. *J Comp Neurol* 2016; 524: 90-118.
- [38] Józwiak-Bebenista M, Kowalczyk E, Nowak JZ. The cyclic AMP effects and neuroprotective activities of PACAP and VIP in cultured astrocytes and neurons exposed to oxygen-glucose deprivation. *Pharmacol Rep* 2015; 67: 332-338.
- [39] Gaist D, Garde E, Blaabjerg M, Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: An MRI study. *Brain* 2016; 139: 2015-2023.
- [40] Shpargel KB, Jalabi W, Jin Y, Preconditioning paradigms and pathways in the brain. *Cleve Clin J Med* 2008; 75: S77-S82.
- [41] Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac preconditioning at a distance. *Am J Physiol Heart Circ Physiol* 2000; 278: H1571-H1576.
- [42] Chai W, Mehrotra S, Jan Danser AH, The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts. *Eur J Pharmacol* 2006; 531: 246-253.
- [43] Li YJ, Peng J. The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. *Eur J Pharmacol* 2002; 442: 173-177.
- [44] Olesen J, Diener HC, Husstedt IW, Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *N Engl J Med* 2004; 350: 1104-1110.
- [45] Amin FM, Hougaard A, Schytz HW, Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. *Brain* 2014; 137: 779-794.
- [46] Juul R, Aakhus S, Björnstad K, Calcitonin gene-related peptide (human alpha-CGRP) counteracts vasoconstriction in human subarachnoid haemorrhage. *Neurosci Lett* 1994; 170: 67-70.
- [47] MaassenVanDenBrink A, Meijer J, Villalón CM, Wiping out CGRP: Potential cardiovascular risks. *Trends Pharmacol Sci* 2016; 37: 779-788.